Jazz Reports First Patient Enrollment in P-II Clinical Trial of JZP150 for the Treatment of Post-Traumatic Stress Disorder
Shots:
- The first patient has been enrolled in a P-II trial to evaluate the safety & efficacy of JZP150 in 270 patients aged 18 to 70yrs. with PTSD across 40 US study sites. The results are expected in YE 2023
- The 1EPs of the trial measures patients change from the start to end of treatment using CAPS-5 score & has multiple 2EPs including changes in scores on the clinical global impressions severity and the patient global impression of severity scales from study start to the end of treatment
- JZP150 is a highly selective inhibitor of FAAH enzyme & has received FTD from the US FDA for PTSD. If approved, JZP150 will be 1st approved product for patients with the same indication
Ref: Jazz | Image: Jazz
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com